Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

HR+/HER2- Advanced Breast Cancer 1

Interventions

pembrolizumab 21Cisplatin 14Carboplatin 13Paclitaxel 12Radiation 11Radiotherapy 10Doxorubicin 10Nivolumab 9Cyclophosphamide 9Cytarabine 8Vincristine 7Radiotherapy, Intensity-Modulated 7Metformin 7Magnetic Resonance Spectroscopy 7Injections 7Etoposide 7Leucovorin 6Ipilimumab 6Fluorouracil 6Docetaxel 6tislelizumab 5Specimen Handling 5Radiotherapy, Conformal 5Radiosurgery 5Prednisone 5Pemetrexed 5Methotrexate 5Dexamethasone 5Cetuximab 5Bevacizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × dalpiciclib × 30 days × Clear all
NCT05586841 2026-05-29

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase â… b Study

Beijing 302 Hospital

Phase 1 Completed
22 enrolled
Breast

HR+/HER2- Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡